Leiden, The Netherlands, October 11, 2007. Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that it has received Orphan Drug designation for recombinant human fibrinogen (rhFIB) from the US Food and Drug Administration (FDA) for the treatment of bleeding in patients deficient in fibrinogen. Pharming has initiated development of recombinant human fibrinogen as a pharmaceutical product for genetic and acquired deficiencies with the orphan designation and will continue to pursue medical device development using rhFIB through partnerships.
